Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Bubalo, P. Carpenter, N. Majhail, M. Perales, D. Marks, P. Shaughnessy, J. Pidala, H. Leather, J. Wingard, B. Savani (2014)
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 20 5
S. Dix, J. Wingard, R. Mullins, I. Jerkunica, T. Davidson, C. Gilmore, R. York, L. Lin, S. Devine, R. Geller, L. Heffner, C. Hillyer, H. Holland, E. Winton, R. Saral (1996)
Association of busulfan area under the curve with veno-occlusive disease following BMT.Bone marrow transplantation, 17 2
Je-Hwan Lee, Seong-jun Choi, Jung-Hee Lee, So-eun Kim, Chan-Jeoung Park, H. Chi, Moo-Song Lee, Jung-shin Lee, Woo-kun Kim, K. Lee (2005)
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantationAnnals of Hematology, 84
S. Ciurea, B. Andersson (2009)
Busulfan in hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15 5
A. Clemmons, Sarah Evans, D. DeRemer, F. Awan (2015)
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?Journal of Oncology Pharmacy Practice, 21
H. Deeg, H. Shulman, J. Anderson, E. Bryant, T. Gooley, J. Slattery, C. Anasetti, A. Fefer, R. Storb, F. Appelbaum (2000)
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.Blood, 95 4
J. Slattery, R. Clift, Buckner Cd, J. Radich, B. Storer, W. Bensinger, E. Soll, C. Anasetti, R. Bowden, E. Bryant, T. Chauncey, H. Deeg, K. Doney, M. Flowers, T. Gooley, J. Hansen, P. Martin, G. McDonald, R. Nash, E. Petersdorf, J. Sanders, G. Schoch, Patricia Stewart, R. Storb, K. Sullivan, Thomas Ed, R. Witherspoon, Appelbaum Fr (1997)
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.Blood, 89 8
B. Andersson, T. Madden, H. Tran, W. Hu, K. Blume, D. Chow, R. Champlin, W. Vaughan (2000)
Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 6 5A
B. Weiss, D. Vogl, N. Berger, E. Stadtmauer, H. Lazarus (2013)
Trimming the fat: obesity and hematopoietic cell transplantationBone Marrow Transplantation, 48
A. Ghobadi, Eric Nolley, Jingxia Liu, A. McBride, K. Stockerl-Goldstein, A. Cashen (2015)
Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failureBone Marrow Transplantation, 50
Carmen Martínez, C. Canals, B. Sarina, E. Alessandrino, D. Karakasis, A. Pulsoni, S. Sica, Marek Trněný, John Snowden, E. Kanfer, N. Milpied, Alberto Bosi, S. Guidi, C. Souza, Roelof Willemze, R. Arranz, L. Jebavý, Andrzej Hellmann, D. Sibon, R. Oneto, J. Luan, P. Dreger, L. Castagna, A. Sureda (2013)
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
C. Aggarwal, Sameer Gupta, W. Vaughan, G. Saylors, D. Salzman, Rhonda Katz, A. Nance, A. Tilden, M. Carabasi (2006)
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 7
R. Walter, S. Buckley, J. Pagel, B. Wood, B. Storer, B. Sandmaier, M. Fang, B. Gyurkocza, C. Delaney, J. Radich, E. Estey, F. Appelbaum (2013)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.Blood, 122 10
M. Sorror, M. Sorror, B. Logan, B. Logan, Xiaochun Zhu, J. Rizzo, K. Cooke, P. McCarthy, V. Ho, M. Horowitz, M. Pasquini (2015)
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 21 8
J. Kim, S. Sohn, Y. Chae, D. Yang, J.-j. Lee, H.J. Kim, H. Shin, J. Jung, W. Kim, D. Kim, C. Suh, S. Kim, H. Eom, S. Bae (2007)
Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphomaBone Marrow Transplantation, 40
W. Navarro, F. Loberiza, Ruta Bajorunaite, K. Besien, J. Vose, H. Lazarus, J. Rizzo (2006)
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 5
V. Brown, M. Zahurak, A. Seung, G. Rosner, Richard Jones, L. Luznik, L. Thomas (2012)
Dosing of Busulfan in Overweight and Obese Patients Compared to Normal Weight Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)Biology of Blood and Marrow Transplantation, 18
M. Sorror, M. Maris, R. Storb, F. Baron, B. Sandmaier, D. Maloney, B. Storer (2005)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.Blood, 106 8
W. Navarro, M. Agovi, B. Logan, K. Ballen, B. Bolwell, H. Frangoul, Vikas Gupta, T. Hahn, V. Ho, M. Juckett, H. Lazarus, M. Litzow, J. Liesveld, J. Moreb, D. Marks, P. McCarthy, M. Pasquini, J. Rizzo (2008)
Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in AdultsBlood, 112
G. McDonald, M. Hinds, L. Fisher, Howard Schoch, J. Wolford, M. Banaji, Barbara Hardin, H. Shulman, R. Clift (1993)
Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 PatientsAnnals of Internal Medicine, 118
L. Nguyen, F. Léger, S. Lennon, C. Puozzo (2005)
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic studyCancer Chemotherapy and Pharmacology, 57
G. McDonald, Pankaj Sharma, David Matthews, H. Shulman, E. Thomas (1984)
Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing FactorsHepatology, 4
R. Dean, B. Pohlman, J. Sweetenham, R. Sobecks, M. Kalaycio, Stephen Smith, E. Copelan, S. Andresen, L. Rybicki, J. Curtis, B. Bolwell (2010)
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non‐Hodgkin lymphoma with busulfan, cyclophosphamide and etoposideBritish Journal of Haematology, 148
B. Andersson, A. Kashyap, V. Gian, J. Wingard, H. Fernandez, P. Cagnoni, Roy Jones, S. Tarantolo, Wendy Hu, K. Blume, S. Forman, R. Champlin (2002)
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 8 3
E. Copelan, T. Bechtel, B. Avalos, P. Elder, S. Ezzone, M. Scholl, S. Penza (2001)
Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantationBone Marrow Transplantation, 27
S. Servais, R. Porcher, A. Xhaard, M. Robin, E. Masson, J. Larghero, P. Ribaud, N. Dhedin, Sarah Abbes, Flore Sicre, G. Socié, R. Latour (2014)
Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donorsHaematologica, 99
M. Hadjibabaie, Hamed Tabeefar, K. Alimoghaddam, M. Iravani, K. Eslami, H. Honarmand, M. Javadi, F. Khatami, A. Ashouri, A. Ghavamzadeh (2012)
The relationship between body mass index and outcomes in leukemic patients undergoing allogeneic hematopoietic stem cell transplantationClinical Transplantation, 26
Weight-based dosing of intravenous busulfan is widely used in hematopoietic cell transplantation. However, a variety of dosing weights have been described. The objective of this retrospective study was to determine the pharmacokinetic impact of using ideal body weight as the initial dosing weight in obese as compared to non-obese transplant recipients. The secondary objectives were to describe the use of alternative dosing weights, the impact on survival, and the rates of toxicities. The mean steady-state concentration was 779.3 ng/mL (n = 82) in the non-obese cohort and 673.7 ng/mL (n = 63) in the obese cohort (p < 0.001). A smaller proportion of concentrations were below goal in the non-obese cohort (10% vs. 41%, p < 0.001). Ideal body weight and adjusted body weights with a 25 and 40% correction factor are appropriate in non-obese patients; adjusted body weights with a 25 and 40% correction factor are appropriate in obese patients. There was no difference in overall survival (p = 0.18); there was a difference in median progression-free survival (1078 vs. 500 days, p = 0.045) in the non-obese compared to obese cohorts. The use of ideal body weight to dose busulfan resulted in lower steady-state concentrations, a larger proportion of subtherapeutic concentrations, and worse progression-free survival in obese patients.
Bone Marrow Transplantation – Springer Journals
Published: Jun 8, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.